ocatini

Ocatini (also known as ZG19018) is an orally bioavailable, small-molecule inhibitor of the KRAS G12C mutant protein, developed by Suzhou Zelgen Biopharmaceuticals. It is designed to selectively and irreversibly bind to the cysteine residue of the KRAS G12C protein, locking it in an inactive GDP-bound state and thereby inhibiting downstream signaling pathways (such as MAPK/ERK) that drive tumor cell proliferation. Ocatini is primarily being investigated for the treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC) and colorectal cancer harboring the KRAS G12C mutation. The drug has shown potent anti-tumor activity in preclinical models and is currently undergoing clinical evaluation in Phase 1/2 trials.

Other names

ocatinibJidunib吉度替尼奥卡替尼